FDA Aligns with Cognition on Lewy Body Study
The FDA and Cognition Therapeutics have reached an agreement on the design of a phase 3 study for the drug zervimesine.
Updated on Oct. 23, 2026 in Alzheimer’s
Live Poll
Should the federal government prioritize funding and support for research into rare neurodegenerative disease treatments?
The FDA and Cognition Therapeutics have finalized the protocol for a phase 3 clinical trial of the drug zervimesine to treat dementia with Lewy bodies. The study aims to address symptoms such as hallucinations and delusions in patients with the condition.
Why it matters
Currently, there are no FDA-approved treatments for dementia with Lewy bodies, making this trial a significant step in potentially filling a critical gap in neurological care. Hallucinations often emerge early in the progression of this disease, severely impacting a patient's quality of life.
The registrational study will administer 100 mg of zervimesine once daily over a 9-month treatment duration. It remains unknown when the trial will officially begin enrolling participants.
The players
FDA
The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of medical products.
Cognition Therapeutics
Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on developing drugs that target neurodegenerative diseases.
The details
The study will evaluate zervimesine’s ability to prevent toxic oligomers from binding to neurons through the sigma-2 receptor. Participants will be randomly assigned to receive either the active 100 mg dose or a placebo to measure improvements in neuropsychiatric symptoms and daily living activities.
Timeline
October 22, 2026: Cognition Therapeutics announced the FDA alignment.
The Big Picture
This trial utilizes the sigma-2 receptor pathway to investigate potential disease-modifying treatments for neurodegeneration. By targeting this mechanism, the study marks a departure from existing therapies that only manage symptoms without addressing underlying neuronal toxicity.
The study offers potential new hope for patients and families currently managing the severe symptoms of dementia with Lewy bodies without approved medication options. Patients interested in the trial will eventually need to monitor updates regarding eligibility and enrollment locations.
The takeaway
This development represents a critical move toward establishing a standardized treatment for a condition that currently lacks any approved clinical protocols. Future trial outcomes will be essential for determining if targeting the sigma-2 receptor can successfully mitigate cognitive impairment.
Further reading
For more on evolving research in this field, visit the Alzheimer’s section.
More information
Read the Cognition Therapeutics phase 3 announcement for more details.
Source note: This article includes information reported by Psychiatrictimes.
Live Poll
Should the federal government prioritize funding and support for research into rare neurodegenerative disease treatments?
